Dr. David Morrison, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 90
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
LA license 09142R · AL license 20819 · CA license C167124 (first issued 2019; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- East Jefferson General Hospital Metairie, LA
Medical groups
- Administrators of the Tulane Educational Fund (393 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 275
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, ondansetron hydrochloride, per 1 mg | 1,256 | 16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 950 | 18 |
| Injection, zoledronic acid, 1 mg | 203 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 159 | 102 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 112 | 26 |
| Injection of drug or substance under skin or into muscle | 108 | 23 |
| Administration of chemotherapy into vein, 1 hour or less | 101 | 23 |
| Collection of blood sample from implanted device | 94 | 20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 70 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 155 payments worth $3,518 in total to this clinician.
| Food and Beverage | $3,411 |
|---|---|
| Education | $107 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Mar 10, 2025 | Education in-kind | $99.95 |
| AstraZeneca Pharmaceuticals LP Jan 14, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $6.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $239,965 in research payments for these studies, mostly to the institutions running them.
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Recruiting · NCT05254743 - Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05471843 - A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
Eli Lilly and Company - A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chro…
Acerta Pharma LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.